Adult Dosing
Prophylaxis and chronic treatment of asthma
Note:
- To be administered at least 1 hr before or 2 hrs after meals
Pediatric Dosing
Prophylaxis and chronic treatment of asthma
- Safety and effectiveness in pediatric patients <5 yrs of age have not been established
- Children 5-11 yrs
- Children 12 yrs and older
Note:
- To be administered at least 1 hr before or 2 hrs after meals
[Outline]
See Supplemental Patient Information
- Life-threatening hepatic failure has been reported in certain patients at therapeutic doses of zafirlukast. However, in most cases, the symptoms abated and the liver enzymes normalized after discontinuation of therapy
- In rare cases, patients treated with zafirlukast either developed fulminant hepatitis or progressed to hepatic failure, liver transplantation, and death
- Patients must be attentive to any signs or symptoms of liver dysfunction (abdominal pain in the right upper quadrant, jaundice, nausea, pruritus, anorexia, flu-like symptoms). If liver dysfunction is suspected, discontinue therapy immediately
- Regular monitoring of LFTs is advised in patients treated with zafirlukast. Early detection of drug-induced hepatic damage and prompt discontinuation of the drug improves the chances of recovery
- Concurrent use of zafirlukast with warfarin may result in a marked increase in prothrombin time (PT). Monitor PT closely in such patients and adjust the warfarin dose accordingly
- Zafirlukast is not a bronchodilator and should not be used to treat bronchospasm in acute asthma attacks and status asthmaticus
- Treatment with zafirlukast should be taken regularly as prescribed and continued even during symptom-free periods
- Systemic eosinophilia, eosinophilic pneumonia, or vasculitis consistent with Churg-Strauss syndrome have been reported rarely with use of zafirlukast
- Withdrawal or dose reduction of zafirlukast may cause aggravation of pulmonary symptoms, eosinophilia, vasculitic rash, cardiac complications, and neuropathy
- Patients and physicians should remain alert to the emergence of neuropsychiatric events such as insomnia and depression during treatment with zafirlukast
Cautions: Use cautiously in
- Hepatic impairment
- Concomitant use of theophylline
- Tapering systemic steroids
- Elderly patients
Supplemental Patient Information
- Instruct patients not to decrease the dose or discontinue any other anti-asthma drugs without physician's recommendation
- Advise patients to immediately contact their physicians on experiencing symptoms of hepatic dysfunction
- Instruct patients to notify their physicians on occurrence of neuropsychiatric events
- Advise patients to take zafirlukast at least 1 hr before or 2 hrs after meals, as its bioavailability may be reduced when taken with food
Accolate interacts with :
Pregnancy Category:B
Breastfeeding: Possibly unsafe. No published experience exists with zafirlukast during lactation; however, manufacturer's data suggest a low dose in human milk. An alternate drug may be preferred, especially while nursing a newborn or preterm infant. This is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 28 June 2011). As per manufacturer's data, zafirlukast should not be administered to nursing mothers.
Pricing data from www.DrugStore.com in U.S.A.
- Zafirlukast 10 MG TABS [Bottle] (PAR)
60 mg = $89.99
180 mg = $249.97 - Accolate 20 MG TABS [Bottle] (ASTRAZENECA)
60 mg = $129.99
180 mg = $375.96 - Accolate 10 MG TABS [Bottle] (ASTRAZENECA)
60 mg = $120.99
180 mg = $340.96 - Zafirlukast 20 MG TABS [Bottle] (PAR)
60 mg = $89.99
180 mg = $249.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Accolate 10 MG Oral Tablet
Ingredient(s): Zafirlukast
Imprint: ACCOLATE10
Color(s): White
Shape: Round
Size (mm): 6.00
Score: 1
Inactive Ingredient(s): croscarmellose sodium / lactose monohydrate / magnesium stearate / povidone / titanium dioxide / hypromellose
Drug Label Author:
AstraZeneca Pharmaceuticals LP
DEA Schedule:
Non-Scheduled
Drug Name: Accolate 20 MG Oral Tablet
Pill Image:
[
See full size image]
Ingredient(s): Zafirlukast
Imprint: ACCOLATE20
Color(s): White
Shape: Round
Size (mm): 8.00
Score: 1
Inactive Ingredient(s): croscarmellose sodium / lactose monohydrate / magnesium stearate / povidone / titanium dioxide / hypromellose
Drug Label Author:
AstraZeneca Pharmaceuticals LP
DEA Schedule:
Non-Scheduled
5 yrs